<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>9</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2015</Year>
        <Month>09</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Newly Identified T Helper 22 Cells Lodge in Leukemia</title>
    <FirstPage>143</FirstPage>
    <LastPage>154</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Gholamreza</FirstName>
        <LastName>Azizi</LastName>
        <affiliation locale="en_US">Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran. AND Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mohsen</FirstName>
        <LastName>Rastegar Pouyani</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Shadi Sadat</FirstName>
        <LastName>Navabi</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Reza</FirstName>
        <LastName>Yazdani</LastName>
        <affiliation locale="en_US">Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. AND Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Kiaee</LastName>
        <affiliation locale="en_US">Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Abbas</FirstName>
        <LastName>Mirshafiey</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>14</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Leukemia is a hematological tumor in which the malignant myeloid or lymphoid subsets play a pivotal role. Newly identified T helper cell 22 (Th22) is a subset of CD4(+) T cells with distinguished gene expression, function and specific properties apart from other known CD4(+) T cell subsets.Th22 cells are characterized by production of a distinct profile of effector cytokines, including interleukin (IL)-22, IL-13, and tumor necrosis factor-&#x3B1; (TNF-&#x3B1;). The levels of Th22 and cytokine IL-22 are increased and positively related to inflammatory and autoimmune disorders. Recently, several studies have reported the changes in frequency and function of Th22 in acute leukemic disorders as AML and ALL. This review discusses the role of Th22 and its cytokine IL-22 in the immunopathogenesis of leukemic disease.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/380</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/380/418</pdf_url>
  </Article>
</Articles>
